Lancet、NEJM罕见“黑色素瘤”病例报道,值得一看!

2016-09-08 MedSci MedSci原创

黑色素瘤虽以“瘤”字结尾,但却是源于色素沉着区域的黑素细胞的恶性肿瘤。可通过血液和淋巴发生转移,恶性程度极高,可在诊断数月后死亡。但早期,非常表浅的病损5年治愈率可为100%。所以治愈率取决于早期诊断,早期治疗!在美国,黑色素瘤在所有皮肤癌病例所占比例不到2%,但所导致的患者死亡率极高。今年,美国新发73000多名黑色素瘤患者,预计近1万名患者将死于黑色素瘤。 医生每天都会遇到各种各

黑色素瘤虽以“瘤”字结尾,但却是源于色素沉着区域的黑素细胞的恶性肿瘤。可通过血液和淋巴发生转移,恶性程度极高,可在诊断数月后死亡。但早期,非常表浅的病损5年治愈率可为100%。所以治愈率取决于早期诊断,早期治疗!

在美国,黑色素瘤在所有皮肤癌病例所占比例不到2%,但所导致的患者死亡率极高。今年,美国新发73000多名黑色素瘤患者,预计近1万名患者将死于黑色素瘤。 

医生每天都会遇到各种各样的疑难杂症,但还有很多临床医生都未接触过的病例,下面梅斯医学小编为大家盘点几例值得一看的黑色素瘤病例报道,供大家学习参考,希望对大家有所帮助。

【1】Lancet:藏在龙纹身中的恶性黑色素瘤

2015年10月,一名42岁白人男性患者因鼻唇沟和眉毛周围瘙痒同时伴有红斑和脱屑而就诊,其症状符合脂溢性皮炎的诊断。

但是,在对患者进行全身皮肤检查时,医生发现,患者的皮肤存在很多色素痣,而且患者的整个背部、手臂以及胸部几乎纹满了龙的纹身。仔细检查发现,患者龙纹身的尾巴处存在一个发育不良痣(如图所示)。问诊后得知患者纹身时间为1年前,而此发育不良痣却至少存在了5年,纹身师有意在痣的周围进行了纹身。患者为II 型皮肤、金发、碧眼,曾在法国外籍兵团工作,长时间接受阳光暴晒。除儿童时期有过晒伤外,患者自述并无其他病史,也未接受任何药物治疗,也无皮肤病家族史。

手术完全切除发育不良痣,切除大小为1cm直径。组织学检查证实为浅表扩散性黑色素瘤,厚0-26 mm。根据美国癌症分期联合委员会(AJCC),肿瘤归为IA期。正常范围内进行额外的筛查。医生对患者进行了防晒医嘱,并根据AJCC建议对IA期黑色素瘤患者进行随访观察。患者并未出现疾病进展的迹象。


藏在纹身中的恶性黑色素瘤

(A)患者的背部照片,显示了藏在纹身中的病损部位(方框内)。(B)切除病损,直径为1cm,稍突出皮肤,边界及颜色不规则,从正常皮肤切入锐切除发育不良痣。(C)组织病理学检查显示为非溃疡性浅表扩散性黑色素瘤,厚0-26 mm,有丝分裂活性最小,并未出现血管或淋巴结浸润。

已有研究报道,许多皮肤病变(良性和恶性)与纹身有关。纹身所致的恶性转化机制尚未可知,所涉及的机制可能包括颜料的毒性作用和紫外线照射下颜料所引起的氧化应激反应以及慢性炎症反应,创伤诱发了现有病损的恶性变化,此外,纹身过程中创伤可致黑色素瘤细胞的扩散。本病例中,患者的不良色素痣并未受到纹身中创伤的影响。虽然纹身并没有看作是导致色素痣恶性化的危险因素,但是,医生应仔细检查纹身,因为纹身有可能会掩盖了恶性病变。(文章详见--Lancet:藏在龙纹身中的恶性黑色素瘤

【2】NEJM:眼睑恶性黑色素瘤——案例报道

患者男,87岁,对左上眼睑麦粒肿进行治疗。保守治疗后麦粒肿没有改善,皮肤色泽也逐渐变暗。并且出现了瘙痒,但没有疼痛或出血。


因为患者以前是救生员,有长时间阳光暴露史,所以是皮肤癌危险人群。因为对患者的左上眼睑缘进行活检,结果显示:侵袭性恶性黑色素瘤!Breslow厚度为0.35毫米,无溃疡、无有丝分裂。


随后对患者进行黑色素瘤的多学科管理的治疗,但是患者拒绝,并失去随访。

原发性眼睑恶性黑色素瘤是罕见的,占皮肤黑色素瘤和眼睑恶性肿瘤总发病率的1%不到。恶性雀斑样痣黑色素瘤是黑色素瘤累及眼睑的最常见的组织学亚型。由于下眼睑比上眼睑更直接的暴露于阳光下,所以发病率也会更高。(文章详见--NEJM:眼睑恶性黑色素瘤——案例报道

【3】NEJM:肢端黑色素瘤案例报道

男性,58岁,左足跟部出现黑色斑块溃疡一年余未愈合而来院就诊。

体格检查可见,黑色斑块溃疡大小为6.5cm*5.5cm。切除活体组织检查,结果显示为肢端黑色素瘤,Breslow分级为深度2mm。左腹股沟淋巴结中的前哨淋巴结活检结果阴性。


在医生的建议下,患者同意行广泛性局部切除,切除范围达到溃疡边缘外2cm。

在术后的2年随访过程中,未见有复发的迹象。

肢端黑色素瘤是一种罕见的变异黑色素瘤,通常发生在手掌和脚掌。它是黑色素瘤中最常见的黑色素瘤组织学类型之一。尽管非西班牙裔白人患者患黑色素瘤的发病率较高,但是,黑人患黑色素瘤(无论是组织学亚型)更容易发展为晚期,且生存率比白人更低。

在本案例中该患者的病情分级为晚期疾病,其原因目前尚未清楚,但很有可能是由于诊治延误导致的。(文章详见--NEJM:肢端黑色素瘤案例报道

【4】NEJM:口腔内黑色素瘤---罕见!

近日,一个60岁的妇女到医院就诊,主诉在她的牙龈上出现黑色色素沉着2个月余。而她既往无吸烟史和饮酒史。

经体查可见,黑色素沉着弥漫性地分布在其上颌前牙的唇侧和腭侧(分别如图A和B所示),无牙齿松动或明显的淋巴结肿大现象。


牙科X线检查中未发现牙齿存在骨质破坏。PET-CT扫描显示在上颌前牙区出现高代谢信号,但未见有淋巴结转移。切口活体检查和组织病理学分析结果显示恶性黑色素瘤。一般情况下,原发性恶性黑色素瘤在口腔中是极其少见的。不幸的是,这种疾病在早期阶段往往没有明显的症状和疼痛,以致于疾病的确诊和治疗大大的延迟。对于这种疾病的患者,只能采取切除病灶并同时进行化疗来联合治疗。

在确诊后的26个月内,医护人员定期对其进行随访,在最后的一次访问中,发现她的病情复发了并出现远处转移现象。(文章详见--NEJM:口腔内黑色素瘤---罕见!

【5】NEJM:髓状皮脂腺痣病例报道

一名12岁的女孩在其头皮表面出现了一块7.0cmX4.0cm大小的黄褐色的斑块。据该女孩主诉,这斑块自其出生以来一直存在,并随年龄的增长不断增大(如图A所示)。

在体格检查,神经系统检查,以及颅骨X线检查均未见明显异常。但取样做组织学病理学检查,结果显示乳头瘤样表皮增生和大量成熟的皮脂腺,可幸的是没有出现癌变的迹象(如图B组所示)。


根据该女孩所出现的临床症状和检查结果,最后医生诊断其患上的是髓状皮脂腺痣。

皮脂腺痣是一种先天性的皮脂腺错构瘤,一般认为是由于HRAS基因和KRAS基因发生突变导致。当皮脂腺痣病变范围广泛时,其演变成一个复杂的综合征,病变可累及到骨骼、眼和神经系统等。由于皮脂腺痣的恶化风险极大,一般建议在青春期前进行手术切除。

对于本案例中患者,属于一种非常罕见的变异案例。为了防止病情出现恶化的情况,该女孩最后接受了手术完全切除和植皮手术。

在术后随访的10个月中,该女孩没有出现复发的现象。(文章详见--NEJM:髓状皮脂腺痣病例报道

【6】NEJM:黑头粉刺样痣

一名19岁的男子称在其左侧锁骨区域出现先天性的皮肤病变(如图A所示),视诊可见扩张毛囊皮脂腺开口与角质栓紧密排列,类似于经典粉刺(如图B)。这些皮脂腺开口均沿左锁骨呈线性分布和延伸到背上,形成了巧妙的色素沉着带,但没有明显的界限。


经体格检查,该男子没有出现相关的神经系统异常或骨骼畸形的现象。取皮肤活组织病理学检查,可见典型的、分组的和扩张毛囊口充满角蛋白,但未见头发轴。

根据该男子的临床症状及检查结果,该男子最终被确诊为患有黑头粉刺样痣。

黑头粉刺样痣,也称毛囊皮脂腺单位的一种错构瘤,是出生即有或在儿童早期发育过程中发生的。其最常见的发病部位是面部、颈部、胸部和上臂,在青春期时会出现加速增长的现象。目前,有人认为患黑头粉刺样痣可能会导致中枢神经系统异常或白内障,但其具体的病理生理尚不明确,怀疑是该病并发炎症或继发感染等原因导致。

对于此病,目前可选择的治疗方案有局部治疗、激光治疗和手术治疗。但由于该男子拒绝进一步干预,只能对其继续进行临床观察。(文章详见--NEJM:黑头粉刺样痣

【7】NEJM:治疗贝克尔痣---爱美之心,人皆有之!

近日,一位15岁的健康小男孩来到皮肤科门诊就诊,对主治医生展现他胸前的一大片色素沉着的区域。据该小男孩反应,他自幼时胸前就有那么一片的色素沉着现象。到了青春期的时候,这种现象更为严重,随后慢慢地开始发展为长出黑色的头发。而经过询问,他的家族里并没有其他的亲属出现过类似的症状。


通过体格检查发现,那些边界清楚的棕褐色斑点附近覆盖着深色的黑毛,这些黑毛覆盖了整个上胸部、右肩和背部(图A和图B)。经过体查后,主治医生最后确断该小男孩患上了贝克尔痣。

其实,长了贝克尔痣并不可怕,因其本身是一种良性的痣,其最大的特点是其色素沉着的外周边缘是不规则的,若不经治疗,数年后色素沉着的部位就会出现长黑毛的现象。而长黑毛的部位通常好发于躯干的上部、肩部和青少年的上臂处。其对患者本身最大的影响就是个人形象的问题。一般的情况下,长有贝克尔痣的人不会有太明显的表现,此种情况下,若患者不是出于美容的考虑,一般都不需做任何的治疗。

注:贝克痣又称Becker色素性毛痣色素性毛发上皮痣。多发于10~20岁男性肩部、前胸或肩胛部的不规则褐色斑表皮轻度角化过度和棘层肥厚,表皮突不规则下延,皮损内一般有粗大的黑色毛发。如出于美容需求可考虑冷冻或手术切除后植皮。(文章详见--NEJM:治疗贝克尔痣---爱美之心,人皆有之!

本文系梅斯医学(MedSci)原创编译整理,欢迎转载!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-11-12 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2017-01-20 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-09-10 syscxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-09-08 知难而进

    很吓人!!!!!!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1680349, encodeId=47c8168034979, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 12 15:40:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828601, encodeId=a7b41828601e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 20 04:40:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467155, encodeId=891f146e15544, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558758, encodeId=89201558e58aa, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564767, encodeId=54a71564e671b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 10 01:40:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114140, encodeId=c917114140dc, content=很吓人!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=114141, encodeId=1fe1114141d0, content=很可怕!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Thu Sep 08 15:36:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-09-08 知难而进

    很可怕!!!!!!

    0

相关资讯

J Am Acad Dermatol:小儿恶性黑色素瘤常模仿皮肤良性病变:回顾性研究

背景:儿童黑色素瘤可能会被误诊,因为它的稀有性和不典型的表现。目的:试图探究儿童黑色素瘤与Breslow深度和临床行为的相关性,识别皮肤科医生和非皮肤科医生的误诊情况。方法:对2000-2015年梅奥诊所诊断为原发性皮肤黑色素瘤的≤21岁患者进行回顾性研究。结果:与临床表现为恶性黑色素瘤相比,模仿皮肤良性病变的小儿恶性黑色素瘤往往更深(>1 mm; OR=5.48; P = .002),有更

NEJM:晚期黑色素瘤会抵抗PD-1 阻断治疗

近日,加州大学洛杉矶分校研究人员发现一种机制,该机制确定了晚期黑色素瘤是如何对免疫检查点抑制剂进行抵抗的,这一发现可能会引起设计新型治疗方案来治疗致命的皮肤癌。“免疫疗法可让我们身体的免疫防御系统抵抗癌症侵袭,但抵抗癌症必须是长期且持续的。”加州大学洛杉矶分校血液学和肿瘤学教授Ribas说。“我们首次了解了肿瘤细胞可以避免被免疫系统T细胞识别,这样就降低了免疫系统对肿瘤细胞攻击的敏感性。”研究人员

Lancet Oncol:治疗黑色素瘤的一线药物cobimetinib+vemurafenib

如先前coBRIM研究的报道,对于未经治疗的BRAFV600突变的晚期黑色素瘤患者,联合使用cobimetinib+vemurafenib,相比安慰剂+vemurafenib,能改善无进展生存期。在这篇文章中,我们报告了最新的疗效结果,包括更长随访时间后的整体生存和安全性,并选定相关生物标志物进行研究。 在这项双盲、随机、安慰剂对照、多中心研究中,经病理证实为BRAFV600突变的IIIC、

喜讯!安进溶瘤免疫疗法获英国NICE批准治疗晚期黑色素瘤

美国生物技术巨头安进(Amgen)溶瘤免疫疗法Imlygic(talimogene laherparepvec,T-vec)近日在英国监管方面迎来转机。英国医疗成本监管机构——英国国家卫生与临床优化研究所(NICE)发布最终指南,支持将Imlygic用于英格兰和威尔士国家卫生服务(NHS)系统,用于治疗已发生局部或远端转移(未发生骨骼、大脑、肺脏或其他内脏转移,IIIB、IIIC、IVM1a期)且

NEJM:黑色素瘤患者PD-1免疫疗法耐药性的机制被揭示

黑色瘤患者接受抗程序性死亡1(PD-1)治疗时的客观反应率约为75%,耐受性良好,效果可持续数年,但是首次用药后仍会出现延迟复发,尽管此时仍在使用抗PD-1治疗。而这种免疫逃避机制尚未可知。研究人员分析了4名转移性黑色素瘤患者基线及复发病损区域的活组织检查样本。这4名患者初次接受抗PD-1治疗(pembrolizumab)后肿瘤消退,但是日后肿瘤复发数月至数年。测定获得性耐药肿瘤细胞的全基因组序列

2016黑色素瘤治疗进展汇总

黑色素瘤,又称恶性黑色素瘤,是来源于黑色素细胞的一类恶性肿瘤,常见于皮肤,亦见于黏膜、眼脉络膜等部位。在亚洲人和有色人种中,原发于皮肤的黑色素瘤占50%~70%,最常见的原发部位为肢端(约占所有黑色素瘤的50%),即足底、足趾、手指末端及甲下等部位,其次为粘膜黑色素瘤(约占20%左右),而欧美白种人这两种亚型仅占所有黑色素瘤的5%。黑色素瘤是皮肤肿瘤中恶性程度最高的瘤种,容易出现远处转移。早期